Kent Pharma manufactures and distributes specialist off-patent and generic pharmaceuticals across the UK, Ireland and other international markets.
Recently acquired by Duke Street Capital as part of a complex carve-out transaction, the business is a market leader in several niche products selling primarily through the hospital and pharmaceutical wholesaler channels. Its portfolio spans several therapeutic areas with particular strengths in analgesics, anti-infectives and penicillins.
With a strong pipeline of new product development already put in place by Kent Pharma’s strong Management Team as well as a focused expansion strategy into other selected branded generics markets across the EMEA region, the business is poised for its next stage of evolution.
Directorbank’s Healthcare specialist Lewis Buckley was approached by Duke Street Capital’s Renée Hoff at the pre-deal stage.
An experienced generics CEO/Chair with a strong track record of working with private equity was required to help get the deal over the line and then take on the role of Non-Executive Chair to support and deliver Kent Pharma’s compelling growth plan.
With support from researcher Tom Warrack, Lewis undertook a thorough search process combining analysis of Directorbank’s Healthcare network, referrals and fresh mapping to identify the most suitable candidates for the role. Three strong candidates were presented for client interview.
Kevin James, an experienced pharmaceutical industry executive, clearly stood out and was offered the role. He since worked tirelessly alongside Duke Street to get the deal through, playing an instrumental role in the process which took around 12 months. Kevin now assumes the role of Chair on the Kent Pharma Board.
Kevin has the ideal combination of skills and experience with a proven track record of launching new products and business units across a range of therapeutic categories.
Most recently he was Chair of Rosemont Pharmaceuticals where he worked alongside CBPE Capital to deliver an ambitious growth plan that culminated in an highly successful exit.
Kevin’s executive career includes the CEO of Intrapharm Laboratories, UK MD of Wyeth Laboratories, the fastest growing UK Pharma company prior to its acquisition by Pfizer with a turnover in excess of $1 billion. He was also Director of Commercial Operations for Lederle Laboratories UK.